The Association of the British Pharmaceutical Industry, a trade group representing UK drug makers, announced that it has reached a voluntary deal with the UK government that involves capping the growth of sales of brand-name drugs to the National Health Service at 2% per year in exchange for faster product launches and speedier appraisals by the National Institute for Clinical Excellence (NICE).
The Association of the British Pharmaceutical Industry (ABPI), a trade group representing UK drug makers, announced that it has reached a voluntary deal with the UK government that involves capping the growth of sales of brand-name drugs to the National Health Service (NHS) at 2% per year in exchange for faster product launches and speedier appraisals by the National Institute for Clinical Excellence (NICE).
Under the Branded Medicines Pricing and Access deal, which is expected to take effect in January 2019 once it has been agreed to in full, the cap applies to the sales of all branded drugs to the NHS, and pharmaceutical companies will repay the NHS for spending that exceeds that limit. According to ABPI, the cap could deliver approximately £930 million (approximately $1.2 billion) in savings in 2019.
In exchange for the 2% cap, the Department of Health and Social Care (DHSC) has agreed that drug makers will receive faster appraisals from NICE, the nation’s health technology assessment body, which could lead to launches expedited by up to 6 months. Drugs recommended by NICE must be funded by the NHS, and the deal, says ABPI, will mean that all new medicines will be receive a NICE appraisal.
According to the DHSC, companies that offer the best-value new medicines will also have “opportunities for greater commercial flexibility.” Price increases of drugs will continue to require DHSC’s approval, however.
ABPI adds that the deal will simplify price controls for pharma; brand-name drug makers that do not participate in voluntary industry—government agreements on drug pricing are currently required to pay to pay the government 7.8% of their sales of products to the NHS. Notably, in August 2018, the UK government proposed bringing biosimilar drugs under these price controls, prompting criticism from the biosimilars industry. Neither ABPI nor DHSC specified whether the simplified price controls under the newly formed deal would encompass biosimilars.
While ABPI has pointed to the 2% maximum as a boon for the NHS, currently, growth in spending on branded drugs is capped at 1.9% for 2018 under the Pharmaceutical Price Regulation Scheme, an agreement that expires at the end of this year and that will be supplanted by the new agreement.
Furthermore, announcement of the agreement comes just as the NHS is poised to slash its yearly spending on brand-name Humira, the costliest drug to the health system, after the arrival of biosimilar adalimumab; this week, the NHS announced that spending on adalimumab would drop by £300 million (approximately $386 million) as it implements biosimilars of the high-cost drug.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.